Adamis Pharmaceuticals Corp (NASDAQ:ADMP) CEO Dennis J. Phd Carlo sold 11,184 shares of the stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $1.73, for a total transaction of $19,348.32. Following the completion of the sale, the chief executive officer now owns 364,407 shares of the company’s stock, valued at approximately $630,424.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
NASDAQ ADMP traded down $0.01 during trading hours on Friday, reaching $1.50. 474,983 shares of the company were exchanged, compared to its average volume of 389,589. Adamis Pharmaceuticals Corp has a 1 year low of $1.49 and a 1 year high of $5.10. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.24 and a current ratio of 1.53. The company has a market capitalization of $70.94 million, a PE ratio of -1.50 and a beta of 1.35.
Adamis Pharmaceuticals (NASDAQ:ADMP) last posted its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.04). Adamis Pharmaceuticals had a negative return on equity of 94.94% and a negative net margin of 239.53%. The company had revenue of $4.91 million for the quarter, compared to analysts’ expectations of $5.95 million. As a group, analysts forecast that Adamis Pharmaceuticals Corp will post -0.49 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in Adamis Pharmaceuticals by 8.4% during the fourth quarter. BlackRock Inc. now owns 963,864 shares of the specialty pharmaceutical company’s stock worth $2,169,000 after buying an additional 74,424 shares during the last quarter. Jane Street Group LLC purchased a new stake in Adamis Pharmaceuticals during the fourth quarter worth about $31,000. Wedbush Securities Inc. purchased a new stake in Adamis Pharmaceuticals during the first quarter worth about $39,000. Vanguard Group Inc increased its holdings in Adamis Pharmaceuticals by 27.1% during the third quarter. Vanguard Group Inc now owns 1,637,513 shares of the specialty pharmaceutical company’s stock worth $5,731,000 after buying an additional 348,645 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Adamis Pharmaceuticals during the first quarter worth about $43,000. Institutional investors and hedge funds own 19.95% of the company’s stock.
Several brokerages have recently commented on ADMP. Maxim Group set a $10.00 target price on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, March 19th. Raymond James set a $4.00 target price on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Friday, May 10th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $5.25.
COPYRIGHT VIOLATION NOTICE: “Adamis Pharmaceuticals Corp (ADMP) CEO Sells $19,348.32 in Stock” was first published by Zolmax and is owned by of Zolmax. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://zolmax.com/investing/adamis-pharmaceuticals-corp-admp-ceo-sells-19348-32-in-stock/3095126.html.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Read More: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.